Ledipasvir-sofosbuvir safe, effective for older HCV patients

A new study has found that a ledipasvir–sofosbuvir combination is safe and effective for older individuals with genotype 1 hepatitis C virus (HCV) infection.

A new study has found that a ledipasvir–sofosbuvir combination is safe and effective for older individuals with genotype 1 hepatitis C virus (HCV) infection. Researchers analyzed sustained virological response at 12 weeks and monitored adverse events, comparing a sample of nearly 2,300 patients aged 65 years and older with a group younger than 65 years. At 12 weeks, 97% of the younger patients and 98% of those aged 65 years and older achieved sustained virological response. The most common adverse events were headache and fatigue. The findings are published in Hepatology.